Compare DSY & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | BDSX |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 122.0M |
| IPO Year | 2023 | 2020 |
| Metric | DSY | BDSX |
|---|---|---|
| Price | $3.08 | $17.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 54.6K | ★ 145.0K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $23.35 |
| Revenue Next Year | N/A | $19.33 |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.17 | $0.25 |
| 52 Week High | $4.03 | $20.21 |
| Indicator | DSY | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 62.32 | 62.15 |
| Support Level | $2.80 | $6.33 |
| Resistance Level | $4.02 | N/A |
| Average True Range (ATR) | 0.35 | 1.86 |
| MACD | -0.08 | 0.08 |
| Stochastic Oscillator | 16.26 | 64.40 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.